文献速递流行病学与生物统计

在Cochrane干预综述中纳入非随机研究证据:一项范围综述

Incorporating non-randomized evidence in cochrane intervention reviews: a scoping review.
PubMed 文献 · J Clin Epidemiol · 2025-05-03

该范围综述识别了2019年或2023年发表于Cochrane Library、纳入非随机干预研究(NRSI)的Cochrane综述共87篇(2019年60篇,2023年27篇),提取NRSI的分析与偏倚风险评估方式及对Cochrane手册指南的遵循程度。总体遵循度低:仅36篇(41%)说明了纳入NRSI的理由,25篇(29%)声明优先使用调整后效应量,6篇将随机对照试验与NRSI纳入同一Meta分析且未说明理由,仅25篇(29%)使用ROBINS-I工具。2019年至2023年间遵循度有所改善但仍较低。

要点

  • 纳入NRSI的Cochrane综述中仅41%(36/87)说明了纳入理由。
  • 仅29%(25/87)声明优先使用调整后效应量,29%(25/87)使用ROBINS-I评估偏倚风险。
  • 6篇综述将RCT与NRSI纳入同一Meta分析且未说明理由。

核心结论

  • Cochrane应考虑如何增加NRSI指南的使用,尤其随着Cochrane科学战略的启动可能增加对纳入NRSI证据综述的需求。

研究设计与样本

  • 范围综述,识别2019年或2023年发表于Cochrane Library、纳入NRSI的Cochrane综述,共87篇(2019年60篇,2023年27篇)。
  • 提取NRSI的分析方式、偏倚风险评估方式及对Cochrane手册指南的遵循程度。

主要发现

  • 总体对指南的遵循度低。
  • 仅36篇(41%)综述说明了纳入NRSI的理由。
  • 仅25篇(29%)综述声明优先使用调整后效应量。
  • 6篇综述将RCT与NRSI纳入同一Meta分析且未说明该方法的理由。
  • 仅25篇(29%)综述使用ROBINS-I工具评估偏倚风险。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: "Non-randomized studies of interventions" (NRSI) can provide valuable insights into the real-world performance of interventions, especially when randomized controlled trials (RCTs) are impractical, unethical, or lack generalizability. We investigated how Cochrane authors have incorporated evidence from NRSI in their reviews and whether this has changed over time. STUDY DESIGN AND SETTING: We conducted a scoping review and identified Cochrane reviews, including NRSI which were published in the Cochrane Library in 2019 or 2023. We extracted data including how NRSI had been analyzed and assessed for risk of bias, and to what extent the authors had followed guidance in the Cochrane Handbook. This allowed us to identify the areas where review authors may need further guidance and support. RESULTS: We identified 87 Cochrane reviews, 60 published in 2019 and 27 in 2023. In general, adherence to the guidance was low. Our key findings were that less than half of the reviews justified the inclusion of NRSI (36 reviews, 41%), less than a third stated prioritizing adjusted effect measures (25 reviews, 29%), and six analyzed RCTs and NRSI in the same meta-analysis, with no justification of this approach. Despite being the recommended tool for use in Cochrane reviews, only 25 reviews (29%) used the Risk Of Bias In Non-randomized Studies-of Interventions (ROBINS-I). We did find that adherence to the guidance improved between 2019 and 2023 but remained low. CONCLUSION: Cochrane should consider how to increase the use of NRSI guidance, especially with the launch of Cochrane's Scientific Strategy, which may lead to an increase in the demand for reviews including NRSI evidence.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Axon E, Kanellopoulou A, Tsokani S, et al. Incorporating non-randomized evidence in cochrane intervention reviews: a scoping review. J Clin Epidemiol. 2025. PMID: 40324697. doi:10.1016/j.jclinepi.2025.111814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。